Immunotherapy in Cancer

Tumor disease over time is a challenge for healthcare professionals in terms of early diagnosis and treatment. By setting the diagnosis on the oncology patient through its detailed examination, many therapeutic algorithms have been proposed and adopted to cure, reduce the likelihood of relapse, and ultimately alleviate relief. In recent years, one more weapon has been added to the battle of cancer in addition to surgical treatment, chemotherapy, radiotherapy, targeted therapies or immunotherapy. Through it, the patient's immune system is activated to destroy cancer cells. Drugs that have been approved and are now widely used are: pebrolizumab, nivolumab, and ipilimumab. Unfortunately, it is accompanied by side effects such as loss of appetite, diarrhea, vomiting, feeling unwell, skin rash, itching, tiredness and reaction at the site of injection. Nurses assess patients, provide information and intervene immediately in case of complications.

Category: Volume 57, N 4
Hits: 87 Hits
Created Date: 15-12-2018
Authors: Dimitrios Papageorgiou , Rafaella Karageorgou